These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Will a 5-ASA a day keep the cancer (and dysplasia) away? Rubin DT; Lashner BA Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769 [TBL] [Abstract][Full Text] [Related]
4. The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven. Terdiman JP Am J Gastroenterol; 2011 Apr; 106(4):737-40. PubMed ID: 21468069 [TBL] [Abstract][Full Text] [Related]
5. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases]. Ioffe AIu Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715 [TBL] [Abstract][Full Text] [Related]
6. 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes. Koelink PJ; Mieremet-Ooms MA; Corver WE; Wolanin K; Hommes DW; Lamers CB; Verspaget HW Inflamm Bowel Dis; 2010 Mar; 16(3):379-89. PubMed ID: 19774649 [TBL] [Abstract][Full Text] [Related]
7. Role of 5-aminosalicylate in preventing colorectal cancer. Riyaz S; Hamlin J; Everett S Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414 [No Abstract] [Full Text] [Related]
8. [5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?]. Desreumaux P; Romano O Gastroenterol Clin Biol; 2004 May; 28(5):509. PubMed ID: 15243337 [No Abstract] [Full Text] [Related]
9. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588 [TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of colorectal cancer in inflammatory bowel disease. Butterworth JR Dig Liver Dis; 2009 May; 41(5):338-9. PubMed ID: 19268635 [No Abstract] [Full Text] [Related]
12. [Colorectal cancer in inflammatory bowel disease]. Henriksen M; Moum B Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155 [TBL] [Abstract][Full Text] [Related]
13. [Mesalamine in the treatment of Crohn disease?]. Nielsen OH; Thomsen OO Ugeskr Laeger; 2005 Apr; 167(15):1656-7. PubMed ID: 15892345 [No Abstract] [Full Text] [Related]
14. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547 [TBL] [Abstract][Full Text] [Related]
15. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation]. MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443 [No Abstract] [Full Text] [Related]
17. Commentary: preventing colorectal cancer with aspirin what next? Logan R Int J Epidemiol; 2007 Oct; 36(5):960-2. PubMed ID: 17921193 [No Abstract] [Full Text] [Related]
18. Commentary: aspirin and colorectal cancer an epidemiological success story. Flossmann E; Rothwell PM Int J Epidemiol; 2007 Oct; 36(5):962-5. PubMed ID: 17954716 [No Abstract] [Full Text] [Related]
19. Mesalamine may be preferable to sulfasalazine in dermatologic therapeutics. Burkhart CG Int J Dermatol; 2006 Jun; 45(6):779-80; author reply 780. PubMed ID: 16796652 [No Abstract] [Full Text] [Related]
20. Point/Counterpoint: Aspirin is clinically effective in chemoprevention of colorectal neoplasia: point. Leshno M; Moshkowitz M; Arber N Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1558-61. PubMed ID: 18628408 [No Abstract] [Full Text] [Related] [Next] [New Search]